In response to the U.S. Supreme Court's holding in Pliva v. Mensing, 131 S. Ct. 2567 (2011), that federal laws and regulations preempted state failure-to-warn claims, the U.S. Food and Drug Administration (FDA) in 2013 proposed to allow generic drug manufacturers to update their warning labels unilaterally. However, last week, the FDA agreed to consider additional industry feedback, opening a new period of public comment that will run until April 27, 2015. The FDA also scheduled a hearing on March 27, 2015, to debate alternative plans for the "communication of important newly acquired drug safety information to health care professionals and the public." This hearing will take place from 8:00 a.m. to 5:00 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (rm. 1503), Silver Spring, MD, 20993-0002.

Registration to attend the hearing must be received by March 20, 2014. Interested parties may also provide FDA with comments on the proposed rule at: http://www.regulations.gov by following the instructions for submitting comments; or by written submission to: Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD, 20852. Submissions must include Docket No. FDA-2013-N-0500 for the proposed rule.